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ABSTRACT  117 
Histone lysine methylation, mediated by mixed-lineage leukemia (MLL) proteins, is 118 
now known to be critical in the regulation of gene expression, genomic stability, cell 119 
cycle and nuclear architecture. Despite being postulated as essential for normal 120 
development, little is known about the specific functions of the different MLL lysine 121 
methyltransferases. Here we report heterozygous variants in the gene KMT2B (also 122 
known as MLL4) in 27 unrelated individuals with a complex progressive childhood-123 
onset dystonia, often associated with a typical facial appearance and characteristic 124 
brain magnetic resonance imaging findings. Over time, the majority of affected 125 
individuals developed prominent cervical, cranial and laryngeal dystonia. Marked 126 
clinical benefit, including the restoration of independent ambulation in some cases, 127 
was observed following deep brain stimulation (DBS). These findings highlight a 128 
clinically recognizable and potentially treatable form of genetic dystonia, 129 
demonstrating the crucial role of KMT2B in the physiological control of voluntary 130 
movement.  131 
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INTRODUCTION 132 
The control of voluntary movement is governed by interactive neural networks 133 
within the brain involving the basal ganglia, sensorimotor cortex, cerebellum and 134 
thalamus1. Disruption of these pathways can lead to a variety of movement 135 
disorders. Dystonia is characterized by sustained or intermittent muscle 136 
contractions causing abnormal, often repetitive, movements and postures affecting 137 
the limbs, trunk, neck and face. Dystonic movements are typically patterned, 138 
twisting, and may be tremulous, often initiated or worsened by voluntary action and 139 
associated with overflow muscle activation2. 140 
Dystonia is described in a broad spectrum of genetic and acquired disorders, either 141 
in isolation or combined with other neurological and systemic features1-5. Despite 142 
genetic advances, the underlying cause remains elusive for a significant proportion 143 
of individuals with childhood-onset dystonia, hindering future prognostication and 144 
treatment strategies6. We report 27 individuals with an early-onset, complex, 145 
combined progressive dystonia associated with mono-allelic variants in KMT2B 146 
(MLL4, NM_014727.2). KMT2B encodes a lysine histone methyltransferase, 147 
involved in H3K4 methylation, an important epigenetic modification associated with 148 
active gene transcription.  149 
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RESULTS 150 
Chromosomal microdeletions and intragenic KMT2B sequence variants in 151 
early-onset dystonia 152 
We identified 34 individuals with undiagnosed childhood-onset dystonia for 153 
molecular genetic investigation (Online Methods, Supplementary Table 1, 154 
Supplementary Fig. 1). On routine diagnostic testing, one case (Patient 1) was 155 
found to have a microdeletion at 19q13.12 of undetermined significance7. 156 
Diagnostic chromosomal microarray was performed in 23/34 individuals and 157 
overlapping microdeletions were detected in a further 5 cases (Supplementary 158 
Table 1, Patients 2-6). Using established external networks (Online Methods, 159 
Supplementary Fig. 1), 4 more cases (Patients 7-10) with microdeletions were 160 
identified. In total, 10 patients (Patients 1-10) had overlapping heterozygous 161 
interstitial microdeletions at 19q13.11-19q13.12 (Table 1, Fig. 1a). Microdeletions 162 
detected on diagnostic microarray were verified by established laboratory protocols 163 
and confirmed as de novo where parental testing was possible (Supplementary 164 
Table 2). The smallest region of overlap extended from 36,191,100-36,229,548bp 165 
(GRCh37/hg19), encompassing two HUGO Gene Nomenclature Committee 166 
curated genes, ZBTB32 (zinc finger and BTB domain containing 32) and KMT2B 167 
(MLL4) (Fig. 1a).  168 
For the remaining 28 cases without a 19q microdeletion, we performed either whole 169 
exome (n=6) or genome sequencing (n=9) in 15 (Online Methods). Heterozygous 170 
sequence variants within KMT2B were identified in 6/15 cases (Patients 13, 14, 17, 171 
21, 22, 27). Sanger sequencing of KMT2B in the other 13 individuals identified one 172 
additional mutation-positive case (Patient 16). Through national and international 173 
collaborations (Online Methods, Supplementary Fig. 1), a further 10 cases 174 
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(Patients 11, 12, 15, 18, 19, 20, 23, 24, 25, 26a) were subsequently ascertained. 175 
Overall, a total of 17 patients with intragenic heterozygous KMT2B variants were 176 
identified (Table 1, Fig.1b). These frameshift insertions (n=1), frameshift deletions 177 
(n=6), splice site (n=1), stop-gain (n=2) and missense (n=7) variants were 178 
confirmed by Sanger sequencing (Supplementary Table 2, 3). Whole exome and 179 
genome analysis did not identify pathogenic variants in (i) ZBTB32, (ii) known 180 
dystonia genes and (iii) genes causing other neurodevelopmental disorders. Where 181 
possible, mutations in TOR1A (NM_000113.2), THAP1 (NM_018105.2) and GNAL 182 
(NM_182978.3) were excluded by diagnostic single gene testing, next generation 183 
multiple gene panels and research Sanger sequencing (Supplementary Table 4). 184 
Parental DNA was available for 23/27 cases, and familial segregation studies 185 
verified that interstitial deletions or intragenic variants had arisen de novo in 20 186 
patients (Supplementary Table 2, Supplementary Fig. 2). Three patients had 187 
maternally inherited missense variants (Patient 22, 26a and 27). The KMT2B 188 
variant identified in Patient 26a had occurred de novo in his symptomatic mother 189 
(Patient 26b) (Supplementary Table 2).  190 
Phenotypic characterization of patients with KMT2B variants 191 
We identified 27 patients (current age 6-40 years, 14 female, 13 male) with KMT2B 192 
variants, who presented with clinical symptoms in childhood (Table 1, Table 2, 193 
Supplementary Table 5, Supplementary Videos 1-7). Individuals presenting in 194 
early childhood (1-9 years, median age 4 years) had either limb or cranio-cervical 195 
symptoms. Clinical presentation for those with microdeletions, frameshift, splice-site 196 
and stop-gain mutations occurred significantly earlier (mean age 4.1 years) than for 197 
those with intragenic missense variants (mean age 6.4 years) (p-value 0.0223) 198 
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(Supplementary Fig. 3). Most patients (21/27) had lower limb symptoms at 199 
disease onset, leading to foot posturing, toe-walking and gait disturbance (Fig. 2a). 200 
4/27 patients presented initially with upper limb symptoms associated with 201 
abnormal postures (Fig. 2b,c) and dystonic tremor, leading to reduced dexterity 202 
and handwriting difficulties (Supplementary Fig. 4a,b). With increasing age, 203 
cervical symptoms (torticollis, retrocollis) (Fig. 2d,e) and cranial involvement (facial 204 
dystonia, oromandibular involvement with dysarthria/anarthria and difficulties in 205 
chewing/swallowing) became prominent features in the majority of patients. In many 206 
patients, progressively severe dysphonia was suggestive of laryngeal involvement. 207 
None of the patients had airway compromise and videostroboscopy was not 208 
undertaken. Over time, most patients (24/27) developed progressive, generalized 209 
dystonia, 2-11 years after initial presentation (Fig. 2f). The dystonia was persistent 210 
in nature, absent in sleep, worsened by voluntary action and associated with 211 
overflow muscle activation. Some patients had dystonic tremor. Sudden, brief, 212 
involuntary muscle jerks, clinically consistent with myoclonus, were evident in 2 213 
cases (Patients 14 and 27). For a few subjects, dystonia was exacerbated when 214 
systemically unwell. Stepwise deterioration following intercurrent illness was 215 
particularly evident in Patient 14, and status dystonicus, triggered by a urinary tract 216 
infection, was reported in Patient 3. 217 
Many patients with KMT2B variants had additional clinical findings, including 218 
microcephaly, seizures, spasticity and eye movement abnormalities (strabismus, 219 
saccade initiation failure and oculomotor apraxia) (Table 2). Dysmorphic features 220 
and characteristic facial appearance (elongated face and bulbous nasal tip) (Fig. 221 
2g, Table 2) were commonly reported. Developmental delay, intellectual disability, 222 
systemic (dermatological, renal, respiratory) features and psychiatric symptoms 223 
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were also present in some individuals (Table 2, Supplementary Table 5, 224 
Supplementary Fig. 4c). Malignancies were not reported in any patients. 225 
Cerebrospinal fluid (CSF) neurotransmitter analysis, undertaken in 13 patients 226 
revealed no major derangement of monoamine metabolites (Supplementary Table 227 
6). Magnetic resonance (MR) imaging revealed a characteristic signature in 17/22 228 
patients who had imaging sequences suitable for assessment (Supplementary 229 
Table 7). Subtle, symmetrical hypointensity of the globus pallidi (with a hypointense 230 
streak of bilateral globus pallidus externa) was evident on MR images known to 231 
demonstrate the magnetic resonance phenomenon of susceptibility (T2, T2*-, 232 
susceptibility- and echo-planar imaging b0-diffusion-imaging datasets) (Fig. 3). 233 
Mean age at neuroimaging was significantly lower for patients with MR 234 
abnormalities (11.7 years) than for those with normal brain scans (19.0 years) (p-235 
value 0.0167) (Supplementary Fig. 5a-c). Single positron emission tomography 236 
using 123I (DaTSCANTM) and 18F-FDG-PET-CT glucose uptake studies, each 237 
undertaken in 3 patients, were normal (Supplementary Table 7, Supplementary 238 
Fig. 5d). 239 
Deep brain stimulation: clinical benefit in KMT2B-dystonia 240 
Overall, medical therapies were not clinically beneficial. None of the patients had a 241 
sustained response to levodopa treatment, nor other commonly used anti-dystonic 242 
agents (Table 1). Ten patients had symptomatic treatment with bilateral globus 243 
pallidus interna-deep brain stimulation (GPi-DBS) (Table 1). All showed clinical 244 
benefit, which was particularly striking in some of the younger patients. Patient 6 245 
showed significant reduction of torticollis and retrocollis, with improvements in 246 
motor function and gait. Patient 8 showed a sustained clinical response 6 years 247 
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after DBS insertion, with improvement of dystonia, even more evident after 248 
replacement of a faulty right DBS lead. Patient 9 had generalized dystonia and 249 
could not walk independently prior to DBS. Two weeks after DBS insertion, he 250 
dramatically regained independent ambulation with marked improvement of 251 
dystonic symptoms (Supplementary Video 8). Patient 17 and 21 were 252 
predominantly wheelchair-dependent prior to DBS insertion, but both patients 253 
showed restoration of independent walking and improvement of dystonia after DBS 254 
(Supplementary Video 9, 10). Patient 19 had amelioration of oromandibular 255 
symptoms with DBS. Patient 20 had DBS inserted at age 32 years and although 256 
most benefits were only transient, sustained improvement of foot posture was 257 
reported. Patient 23 had significant reduction of dystonic symptoms after DBS 258 
insertion. Patient 22, 9 months after DBS insertion (Supplementary Video 11) and 259 
Patient 25, 4 months after DBS insertion, have both shown significant gains in hand 260 
function and independent walking with improvement of dystonia. Five patients are 261 
now over three years post-DBS insertion, and all report a sustained reduction in 262 
dystonia, with restoration of function and prevention of progressive disability. 263 
KMT2B is constrained for missense and predicted protein truncating variants 264 
Patient 13, 14, 17 and 21 had whole genome sequencing as part of the NIHR-265 
funded BioResource-Rare Disease project. Enrichment analysis was undertaken in 266 
this cohort to determine whether predicted protein truncating variants (PPTVs) in 267 
KMT2B were observed more frequently in patients than would be expected by 268 
chance. Given the size and sequence context of KMT2B, 5.73x10-03 de novo 269 
KMT2B PPTVs would be expected to occur by chance in the subset of the NIHR 270 
BioResource-Rare Diseases cohort with pediatric onset neurological disease, but 3 271 
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PPTVs were observed. This represents a significant enrichment (p-value 3.12x10-272 
08). Furthermore in ExAC, KMT2B is highly constrained for PPTVs (accessed July 273 
2016)8 providing supportive evidence of its potential involvement in disease. 712 274 
KMT2B missense variants are reported in the ExAC database. Most of these are 275 
rare, as expected for a cohort of this size, and the median CADD score9 for these 276 
variants is 22.9. The median CADD score for missense variants identified in our 277 
KMT2B-dystonia cohort is significantly higher at 29.1 (p-value 0.0001364; 278 
Supplementary Table 3). Given the size and sequence context of KMT2B, 956 279 
missense variants are predicted to occur by chance, suggesting that KMT2B may 280 
also be constrained for missense variation (z=4.06)8. 281 
KMT2B variants are predicted to destabilize protein structure 282 
In silico homology modelling studies were undertaken to generate hypotheses 283 
regarding the predicted effects of sequence variants on KMT2B (NP_055542.1) 284 
structure-function properties (Supplementary Notes). Based on Pfam domain 285 
assignments, KMT2B has a CXXC zinc finger domain, multiple PHD domains, an 286 
F/Y rich N-terminus (FYRN), FYRC (F/Y rich C-terminus) domain and a C-terminal 287 
SET domain (Fig. 4a). The modelled variants occurred in residues within the PHD-288 
like, FYRN, SET and FYRC-SET linking domains (Fig. 4b-d). Evaluation of a 289 
number of variants using MAESTRO10 and DUET11 suggests a change in the free 290 
energy, with a predicted structure destabilizing effect (Supplementary Notes). 291 
p.Phe1662Leu and p.Gly1652Asp occur within a PHD-like domain (residues 1574-292 
1688), predicted to facilitate interaction with DNA, protein-protein interaction and 293 
recognition of methylated/unmethylated lysines12-14. Extensive hydrophobic 294 
interactions hold the globular structure of this region, which is important for its 295 
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function12. Phe1662 is fully buried at the core, stabilizing the structure of this PHD-296 
like domain while Gly1652 is partially buried (Fig. 4b,e,f). Phe1662 is involved in 297 
multiple hydrophobic contacts at the core of the PHD domain, and exchange for 298 
leucine is predicted to cause loss of contacts at the core (Fig. 4g). Gly1652 is 299 
located on a loop (Fig. 4e) and substitution to aspartic acid is predicted to alter 300 
surface charge, with possible effects on the interaction network in the vicinity, 301 
involving a positively charged Arg1635 which is part of the helix α3 implicated in 302 
DNA binding12. Arg1762 and Leu1781 occur in a FYRN domain. FYRN and FYRC 303 
regions, particularly common in MLL histone methyltransferases, interact to form a 304 
compact structural unit (Fig. 4c,h) important in maintaining the active structure15,16. 305 
Arg1762 forms hydrogen bonds with the backbone carboxyls of Arg2463 and 306 
Leu2464 of FYRC domain. Substitution of Arg1762 by cysteine is predicted to 307 
abolish these contacts and hence contribute to destabilization of FYRC-FYRN 308 
association. Leu1781, at the interface between FYRN and FYRC (Fig. 4h,i) is 309 
surface exposed and involved in backbone hydrogen bonds stabilizing the beta 310 
sheet formed together by the two domains. Substitution to proline (p.Leu1781Pro) is 311 
predicted to disrupt the backbone hydrogen bond at this position, because it lacks 312 
one hydrogen bond donor and its backbone torsion angles are not compatible with 313 
that of a beta sheet. This predicts a destabilizing effect on sheet structure, 314 
potentially affecting the normal association of FYRN and FYRC domains. Arg2517 315 
resides in the region linking FYRC and SET domains, known to bind WDR5, an 316 
effector required for trimethylation of histone H317, presenting methylated histone 317 
H3 substrates to the MLL complex for further methylation18. Arg2517 is thought to 318 
be involved in a salt-bridge interaction with Asp172 of WDR5 (NP_438172.1) (Fig. 319 
4j) and Arg2517Trp is predicted to lead to loss of this interaction. Ile2674, Tyr2688 320 
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and Ile2694 all occur in the catalytic methyltransferase SET domain common to 321 
histone lysine methyltransferases. Ile2674 is buried in the hydrophobic core, 322 
adjacent to the catalytic site (Fig. 4d,k). Substitution to threonine is predicted to 323 
lead to loss of contacts at the core of the domain (due to the shorter side chain) and 324 
also introduces a buried polar group (Fig. 4l). p.Tyr2688Thr occurs at the core of 325 
SET domain involving extensive hydrophobic interactions and a hydrogen bond 326 
interaction with Ser2661 (Fig. 4m). The frameshift mutation p.Tyr2688Thrfs*50, 327 
with insertion of 50 additional residues, is predicted to destabilise the core and 328 
affect contacts due to the substitution with a shorter non-aromatic side-chain. 329 
Ile2694 is involved in the extensive hydrophobic contacts stabilizing the core of this 330 
domain. In silico analysis predicts that the frameshift mutation p.Ile2694Serfs*44 331 
will disrupt the domain fold and affect methyltransferase activity. 332 
KMT2B is ubiquitously expressed with reduced expression in KMT2B-333 
dystonia 334 
We confirmed widespread KMT2B expression in a variety of control fetal and adult 335 
human tissues (Fig. 5a, Supplementary Fig. 6). Moreover, KMT2B is ubiquitously 336 
expressed in the brain with higher expression in the cerebellum than in any other 337 
region (Fig. 5b). We ascertained fibroblasts from all patients consented for 338 
research testing (Patients 2, 13, 14, 16, all with microdeletions or PPTVs in KMT2B) 339 
and detected a statistically significant decrease in fibroblast KMT2B expression on 340 
quantitative RT-PCR when compared to control fibroblasts (Fig. 5c).  341 
Histone H3K4 methylation is not globally reduced in KMT2B-dystonia  342 
To determine the effect of KMT2B variants on methylation of lysine 4 on histone H3 343 
(H3K4 methylation), we assayed tri-methylated H3K4 (H3K4me3) and di-344 
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methylated H3K4 (H3K4me2). Immunoblotting of histones extracted from fibroblasts 345 
of Patients 14 and 16 showed no significant reduction in H3K4me3 or H3K4me2 346 
relative to control samples (Fig. 5d, Supplementary Fig. 7a). A Dictyostelium 347 
discoideum model was used to test the effect of SET domain variant p.Ile2647Thr 348 
on in vivo histone methyltransferase activity. The SET domain of KMT2B shares 349 
56% sequence identity with the Dictyostelium orthologue DdSet1, and Ile2647 is 350 
conserved (corresponding residue in Dictyostelium is Ile1447, XP_636258.1) 351 
(Supplementary Fig. 8f). DdSet1 is the only H3K4 methyltransferase in 352 
Dictyostelium and targeted knockout of DdSet1 (set1-) results in loss of all 353 
methylation at H3K419. We constitutively expressed wild-type DdSet1 (WT-DdSet1) 354 
and mutant-DdSet1 (m-DdSet1), both with N-terminal GFP fusions, in set1- 355 
Dictyostelium cells and compared the resulting levels of H3K4 methylation. 356 
Expression of either GFP-WT-DdSet1 or GFP-mDdSet1 in set1- cells resulted in 357 
rescue of H3K4 tri-methylation to wild type levels (Fig. 5e, Supplementary Fig. 358 
7b,c). 359 
Altered gene and protein expression in KMT2B-dystonia 360 
In order to determine whether KMT2B-dystonia is associated with dysregulation of 361 
specific genes and proteins, we investigated (i) gene and protein expression 362 
profiles for THAP1 and Torsin-1A in cultured patient fibroblasts from Patients 2, 13, 363 
14 and 16 and (ii) tyrosine hydroxylase and dopamine 2 receptor (D2R) protein 364 
levels in cerebrospinal fluid from Patients 2 and 16 (Supplementary Notes, 365 
Supplementary Fig. 9, Supplementary Fig. 10). We found significantly reduced 366 
transcript levels of THAP1 and TOR1A when compared to control fibroblasts 367 
(Supplementary Fig. 11a). Fibroblast immunoblotting studies showed a statistically 368 
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significant reduction in THAP1 protein expression in all 4 patients when compared 369 
to control samples (Supplementary Fig. 11b). A statistically significant reduction in 370 
Torsin-1A was evident in Patient 14, though not in other patients (Supplementary 371 
Fig. 11c). CSF immunoblotting revealed significantly reduced levels of dopamine 2 372 
receptor (D2R) and increase in tyrosine hydroxylase (TH) levels (Supplementary 373 
Fig. 11d). 374 
 375 
DISCUSSION 376 
We report 27 individuals with heterozygous variants in the lysine methyltransferase 377 
gene, KMT2B, and define a new genetic movement disorder that, importantly, is 378 
amenable to treatment with DBS. Using the current classification system2, KMT2B-379 
dystonia is defined as an inherited autosomal dominant, complex, combined 380 
dystonia usually of infantile or childhood-onset. In most patients, the dystonia is 381 
persistent and progressive in nature. Most individuals develop 4-limb dystonia with 382 
particularly prominent cervical, laryngeal and oromandibular symptoms. Whilst the 383 
majority of patients seem to follow this disease trajectory, we also report one young 384 
case (Patient 10, age 7 years) with developmental delay and intermittent toe-385 
walking only. Furthermore, we describe atypical cases with mainly oromandibular 386 
features (Patient 18) or paroxysmal cervical dystonia (Patient 26a) and relatively 387 
little upper or lower limb involvement. 388 
For many patients, KMT2B-dystonia is associated with a number of additional 389 
clinical features including other neurological symptoms, intellectual disability, 390 
psychiatric co-morbidity, dysmorphia, skin lesions and other systemic signs. Given 391 
the association with active gene expression, it is conceivable that KMT2B variants 392 
could account for these additional disease features. For Patients 1-10, other genes 393 
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within the 19q microdeletion may also contribute to aspects of their clinical 394 
phenotype20. KMT2B variants therefore cause a complex dystonia, and affected 395 
patients should have close surveillance of development during childhood, regular 396 
neurology assessments, routine dermatological review and formal neuropsychiatric 397 
testing. 398 
In KMT2B-dystonia, the majority of patients had a characteristic pattern on MR 399 
imaging, with subtle, low pallidal signal on T2*-, diffusion- and susceptibility-400 
weighted sequences, particularly affecting the lateral aspect of the globus pallidus 401 
externa (Fig. 3). Genotype did not appear to influence MR findings. However, those 402 
with abnormal imaging had scans undertaken at a significantly younger age than 403 
those with normal imaging. MR abnormalities may possibly be an age-dependent 404 
phenomenon, perhaps becoming less apparent with increasing age, as evident in 405 
serial imaging from Patient 22 (Supplementary Table 7, Supplementary Fig. 406 
5b,c). The overall significance of these neuroradiological abnormalities remains 407 
unclear. Such findings are reminiscent of, but subtly different to, those reported in 408 
Neurodegeneration with Brain Iron Accumulation (NBIA) syndromes21,22. Similar 409 
non-specific features of T2*-weighted hypointensity are increasingly recognized in 410 
other neurological conditions, including Huntington’s disease, TUBB4A-related 411 
disorders, GM1 gangliosidosis, alpha-fucosidosis and mitochondriocytopathies. 412 
KMT2B variants were identified in 13/34 (38%) individuals with a relatively 413 
homogenous phenotype of early onset progressive dystonia. For externally 414 
screened cohorts, detection rates varied from 1.3-30% according to the phenotypic 415 
focus of the cohort (Supplementary Fig. 1). For cases where KMT2B mutations 416 
were not detected, it is likely that another etiology accounts for their symptoms. 417 
However, it is possible that KMT2B mutations may have been missed as (i) 418 
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single/multiple exon KMT2B deletions and duplications may not be detected on 419 
microarray, Sanger sequencing and whole exome/genome sequencing and (ii) 420 
promoter mutations and intronic KMT2B variants may not have been identified by 421 
whole exome and Sanger sequencing. 422 
The majority of individuals with KMT2B variants (Patients 1-20) had either 423 
heterozygous interstitial microdeletions leading to KMT2B haploinsufficiency or 424 
variants predicted to cause protein truncation, protein elongation, splicing defects or 425 
nonsense-mediated mRNA decay. The remaining 7 patients (Patients 21-27) had 426 
non-synonymous variants of KMT2B. Although a degree of caution must be 427 
exercised for missense variants, those identified in our cohort are (i) described in 428 
patients with a compatible phenotype, (ii) predicted to affect conserved residues 429 
within key protein domains for 5/7 cases (Supplementary Fig. 8, Supplementary 430 
Fig. 12) and (iii) predicted by in silico tools to be deleterious with a destabilizing 431 
effect on protein structure (Supplementary Table 3). Initial disease presentation 432 
was significantly earlier in those with missense variants (Supplementary Fig. 3) 433 
though genotype did not seem to influence subsequent rate of symptom evolution, 434 
disease severity or DBS response. 435 
For the majority of patients, KMT2B variants were confirmed as de novo where 436 
parental testing could be undertaken. In our cohort, 3 patients had missense 437 
changes that were maternally inherited (Patient 22, 26a, 27). The possibility of 438 
imprinting at the disease locus was considered, but deemed unlikely, given that (i) 439 
de novo microdeletions in Patients 2 and 10 occurred on paternally inherited alleles 440 
and (ii) there is bi-allelic expression of KMT2B single nucleotide polymorphisms in 441 
human tissues, including brain (Supplementary Fig. 13). Importantly, whole exome 442 
sequence analysis undertaken in Patients 22, 26a and 27 did not identify other rare 443 
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or de novo variants to account for disease. Interestingly, Patient 26a inherited 444 
p.Arg2517Trp from his symptomatic mother (26b) in whom the change occurred de 445 
novo (Supplementary Fig. 2). She was more mildly affected, with onset of 446 
symptoms in early adulthood, reporting gait abnormalities, progressive inability to 447 
run and periodic paroxysmal upper limb and neck dystonia. Both had similar facial 448 
appearances to others in the cohort (Fig. 2g). In contrast, the mothers of Patients 449 
22 and 27 were clinically examined and neither had evidence of a motor phenotype, 450 
intellectual disability, other neurological features, neuropsychiatric symptoms, facial 451 
dysmorphia, skin lesions or other systemic signs. The identification of both 452 
symptomatic and asymptomatic carriers suggests either ‘apparent’ incomplete 453 
penetrance, due to parental mosaicism, or true incomplete disease penetrance, a 454 
phenomenon commonly reported in other autosomal dominant genetic 455 
dystonias23,24. Other genetic, epigenetic and environmental modifiers may also 456 
influence disease penetrance and phenotypic presentation in KMT2B-dystonia. 457 
KMT2B encodes a ubiquitously expressed lysine methyltransferase specifically 458 
involved in H3K4 methylation25,26, an important epigenetic modification associated 459 
with active transcription. H3K4me3 is enriched at promoters, marking transcription 460 
start sites of actively transcribed genes, whereas H3K4me1 is associated with 461 
active enhancer sequences27. H3K4me2 is less specifically localized, but may be 462 
enriched at transcription factor binding sites28. Members of the SET/MLL protein 463 
family, including KMT2B, are responsible for the generation of H3K4me1, 464 
H3K4me2, and H3K4me3 which are essential for gene activation in normal 465 
development29. Using patient-derived fibroblasts and a Dictyostelium discoideum 466 
model, we demonstrated that KMT2B variants are not associated with widespread 467 
alterations in overall levels of H3K4 methylation. This is not surprising, given that 468 
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haploinsufficiency of other MLL family members have not been convincingly shown 469 
to affect global H3K4 levels. The fundamental physiological role of MLL proteins is 470 
affirmed by the observation that loss-of-function heterozygous mutations in MLL-471 
encoding genes are reported in a number of human developmental disorders30, 472 
namely Wiedemann Steiner (KMT2A, MLL1)31, Kleefstra-like (KMT2C, MLL3)32 and 473 
Kabuki (KMT2D, MLL2)33 syndromes, and most recently SETD1A-related disease 474 
(KMT2F)34. Although physiological functions of MLL proteins are yet to be fully 475 
characterized, the observation that mutations in different MLL genes cause 476 
phenotypically distinct syndromes (Supplementary Table 8) suggests that each 477 
MLL protein has a unique role, regulating the expression of a specific set of 478 
genes35,36. 479 
Amongst the previously reported MLL-gene disorders, dystonia appears fairly 480 
specific to KMT2B-related disease and is not commonly described in other MLL 481 
syndromes (Supplementary Table 8), providing further evidence that different MLL 482 
proteins mediate the activation and transcription of a specific set of genes, with 483 
temporal and cellular context37. In order to determine downstream effects of KMT2B 484 
mutations, we investigated expression profiles of specific genes and proteins 485 
implicated in the pathogenesis of dystonia using patient-derived fibroblasts and 486 
CSF (Supplementary Notes; Supplementary Fig. 9-11). We detected a 487 
statistically significant reduction of THAP1 and TOR1A gene expression and 488 
decreased THAP1 protein expression in fibroblasts. CSF immunoblotting studies 489 
revealed reduction of D2R protein and increase in TH levels in two patients with 490 
KMT2B-dystonia when compared to control CSF samples. The mechanisms 491 
causing such alterations in KMT2B-dystonia remain yet to be elucidated. Whilst 492 
H3K4 methylation is clearly associated with the process of active transcription, 493 
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several studies have shown that H3K4 methylation is required, not for absolute 494 
transcriptional output, but rather for transcription stability or consistency38,39, so the 495 
effects of KMT2B haploinsufficiency could conceivably operate via an intermediary 496 
sensitive to stochastic fluctuations. It is highly likely that dysregulation of other 497 
genes and proteins are also involved in the disease pathophysiology of KMT2B-498 
dystonia. Further studies will determine whether expression profiles of other genes 499 
and proteins are affected in KMT2B-dystonia and contributory to the phenotype. 500 
In conclusion, we report KMT2B variants in 27 patients with a clinically recognizable 501 
form of dystonia. To date, the underlying genetic etiology is only resolved in a 502 
minority of childhood-onset cases of dystonia, which precludes confirmatory 503 
diagnosis, accurate disease prognostication and selection of appropriate treatment 504 
strategies. We have shown that many patients with KMT2B-dystonia have 505 
significant, sustained clinical improvement with DBS. Referral for DBS assessment 506 
should therefore be considered for this group. Identification of additional cases will 507 
allow further characterization of the full phenotypic disease spectrum. Our report 508 
highlights mutations in KMT2B as a new and important cause of complex early-509 
onset dystonia, emphasizing the crucial role of KMT2B in the control of voluntary 510 
movement. 511 
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URLs:  512 
Exome Aggregation Consortium (ExAC) database (accessed July 2016) 513 
http://exac.broadinstitute.org  514 
DECIPHER  515 
http://decipher.sanger.ac.uk 516 
UK10K Project 517 
http://www.uk10k.org 518 
Deciphering Developmental Disorders (DDD) study 519 
http://www.ddduk.org/ 520 
1000 Genomes 521 
http://browser.1000genomes.org/index.html 522 
NHLBI GO Exome Sequencing Project (release 20130513) 523 
http://evs.gs.washington.edu/EVS/ 524 
Ensembl genome browser 525 
http://www.ensembl.org/index.html 526 
Primer3 527 
http://bioinfo.ut.ee/primer3/ 528 
Chromas Sequencing software  529 
http://www.technelysium.com.au/chromas.html 530 
Clustal Omega 531 
http://www.ebi.ac.uk/Tools/msa/clustalo/ 532 
SIFT 533 
http://sift.jcvi.org/ 534 
PolyPhen-2 535 
http://genetics.bwh.harvard.edu/pph2/ 536 
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Mutation Taster 537 
http://www.mutationtaster.org/ 538 
Combined Annotation Dependent Depletion (CADD) 539 
http://cadd.gs.washington.edu/ 540 
BRAINEAC 541 
http://www.braineac.org. 542 
Methods:  543 
Methods and any associated references are available in the online version of the 544 
paper. 545 
Accession codes: 546 
Chromosomal microarray data: Microarray data for Patient 1 (Ref: 326759), 547 
Patient 2 (Ref: 326749), Patient 3 (Ref: 326748), Patient 4 (Ref: 326751), Patient 5 548 
(Ref: 326750), Patient 6 (Ref: 326752), Patient 7 (Ref: 285035) and Patient 8 (Ref: 549 
280902) are deposited in DECIPHER. The data from Patient 1 (Ref: 326759) and 550 
Patient 8 (Ref: 280902) is publically available. The remaining patients did not 551 
consent for their data to be publicly released. 552 
https://decipher.sanger.ac.uk/search?q=326759#consented-patients/results 553 
https://decipher.sanger.ac.uk/search?q=280902#consented-patients/results 554 
NIHR BioResource-Rare Diseases (NIHRBR-RD) Study: Whole genome 555 
sequencing data is deposited in the NIHR BioResource Rare Diseases BRIDGE 556 
consortium sequencing projects (short name: NIHR-BR-RD). Accession code: 557 
EGAS00001001012. Title of dataset: SPEED childhood dystonia KMT2B dataset: 558 
EGAD00001002730. Data is deposited for Patient 1 (Ref: EGAR00001314765); 559 
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Patient 13 (Ref: EGAR00001320121); Patient 14 (Ref: EGAR00001314777); 560 
Patient 17 (Ref: EGAR00001314751) and Patient 21 (Ref: EGAR00001314767). 561 
https://www.ebi.ac.uk/ega/home 562 
UK10K Project: UK10K whole exome sequencing data has been deposited under 563 
the name UK10K_RARE_FIND. Accession code: EGAS00001000128. Title of 564 
dataset: UK10K_RARE_FIND REL-2013-10-31 variant calling: EGAD00001000750 565 
Data is deposited for Patients 22 (Ref: UK10K_FIND5536224) and 27 (Ref: 566 
UK10K_FIND5536279). 567 
https://www.ebi.ac.uk/ega/studies/EGAS00001000128 568 
Deciphering Developmental Disorders (DDD) study: Exome sequencing data is 569 
accessible via the European Genome-phenome Archive (EGA) under accession 570 
EGAS00001000775. 571 
https://www.ebi.ac.uk/ega/studies/EGAS00001000775 572 
National Institutes of Health, Bethesda; Institute of Human Genetics, 573 
Erlangen; Radboud University Medical Center, Nijmegen, UCL-Institute of 574 
Neurology, London: Whole exome sequencing data has not been deposited since 575 
participating patients have not consented for the data to be publicly released.  576 
 577 
Note:  578 
Any Supplementary Information and Source Data files are available in the online 579 
version of the paper. 580 
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Figure legends 770 
Figure 1: 771 
Molecular Genetics Findings in Patients with KMT2B Variants 772 
(a) Top panel: Schematic representation of chromosome 19. Middle panel: Ten 773 
microdeletions on 19q13.11-19q13.12 (GRCh37/hg19). Lower panel: The smallest region 774 
of overlap comprising two genes, ZBTB32 and KMT2B. (b) Schematic exon-intron 775 
structure of KMT2B (NCBI Reference Sequence: NM_014727.2) indicating 7 frameshift 776 
insertions and deletions, 2 stop-gain mutations, 1 splice site variant and 7 missense 777 
changes. 778 
 779 
Figure 2: 780 
Clinical Features of Patients with KMT2B Variants 781 
(a) Patient 17, age 13 years: gait disturbance with dystonic posturing of the four limbs. (b) 782 
Patient 27, age 19 years and (c) Patient 14, age 18 years: bilateral upper limb dystonic 783 
posturing. (d,e) Patient 23, age 8 years: retrocollis. (f) Patient 12, age 6 years: generalized 784 
dystonia, with jaw-opening dystonia and 4-limb posturing. (g) Montage of patient faces: 785 
Top row (left to right) Patients 1, 2, 3, 4, 8, 9; middle row (left to right) Patients 11, 12, 13, 786 
14, 16, 17 and bottom row (left to right) Patients 21, 23, 25, 26a, 26b. Consent to publish 787 
patient photographs has been obtained. Facial elongation, broad nasal base and bulbous 788 
nasal tip evident in some patients. 789 
 790 
Figure 3: 791 
Radiological Features of Patients with KMT2B Variants 792 
Magnetic resonance imaging (MRI) with T2*-weighted (a,d) and T2-weighted images (b,c), 793 
echo-planar technique diffusion-imaging datasets images with b-value of zero (e-h) and 794 
susceptibility weighted sequences (i-l). Abnormal findings indicated by yellow arrows. 795 
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(a,e,i) Representative MRI from control subjects for T2*-weighted sequences (a: age 796 
10y2m), diffusion-weighted sequences (e: age 10y4m) and susceptibility weighted 797 
sequences (i: age 10y8m) indicating normal appearances of basal ganglia. Patient 1, age 798 
9y5m (b,f,j), Patient 13, age 11y3m (c,g,k), Patient 9, age 15y1m (d), Patient 22, age 799 
13y1m (h) and Patient 25, age 16y (l): evidence of bilateral subtle hypointensity of the 800 
globus pallidus with hypointense lateral streak of globus pallidus externa. 801 
 802 
Figure 4: 803 
Comparative Modelling of KMT2B Protein Structure 804 
(a) Schematic domain architecture of KMT2B. (b-d) Degree of amino conservation is 805 
displayed in the structural models for different domains. Red to blue indicates increasing 806 
conservation. (b) Model of PHD-like domain shows Gly1652 and Phe1662. (c) Model of 807 
FYRN domain presents position and conservation of Arg1762 and Leu1781. (d) Model of 808 
the SET methyltransferase domain indicates position and conservation of Ile2674, 809 
Tyr2688 and Ile2694. (e) Location of Gly1652 in the PHD-like domain model and the 810 
hydrogen bond network in the vicinity (α3 helix is indicated). (f) Hydrophobic packing 811 
involving Phe1662. (g) Change to leucine at 1662 is predicted to cause loss of contacts 812 
within the hydrophobic core. Residue side chains are presented as spheres highlighting 813 
van der Waals contacts. (h) Interactions involving Arg1762 from FYRN with Arg2463 and 814 
Leu2464 of FYRC. The hydrogen bond interactions and distances are highlighted. (i) 815 
Leu1781 shown at the interface of FYRN (orange)/FYRC (magenta) domains. The 816 
backbone hydrogen bonds stabilizing the sheet structure are highlighted. (j) Interactions 817 
involving Arg2517 and WDR5 (beige). The salt bridge interaction between Arg2517 of 818 
KMT2B and Asp172 of WDR5 is highlighted. (k) Location and contacts involving Ile2674 in 819 
the hydrophobic core of the SET domain (SAH is indicated). (l) Substitution with threonine 820 
at 2674 is predicted to result in loss of contacts in the hydrophobic core. (m) Interactions 821 
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involving Tyr2688 and Ile2694 in the core of the SET domain. The hydrogen bond 822 
between Tyr2688 and Ser2661 is highlighted. 823 
 824 
Figure 5: 825 
KMT2B Expression and Effects on Histone H3K4 Methylation 826 
(a) PCR analysis of human fetal and adult cDNA for expression of KMT2B (cropped gel 827 
image; for uncropped image see Supplementary Fig. 6). KMT2B is widely expressed in 828 
human tissues, including fibroblasts, brain tissue and midbrain dopaminergic neurons. (b) 829 
Box plots of KMT2B mRNA expression levels in 10 adult brain regions (source: 830 
BRAINEAC; http://www.braineac.org/). Expression levels are based on exon array 831 
experiments as previously described and plotted on a log2 scale (y axis)40. KMT2B is 832 
ubiquitously expressed across all 10 brain regions analyzed, with expression highest in the 833 
cerebellum. Putamen (PUTM), frontal cortex (FCTX), temporal cortex (TCTX), occipital 834 
cortex (OCTX). hippocampus (HIPP), substantia nigra (SNIG), medulla (specifically inferior 835 
olivary nucleus, MEDU), intralobular white matter (WHMT), thalamus (THAL), and 836 
cerebellar cortex (CRBL). “N” indicates the number of brain samples analyzed to generate 837 
the results for each brain region. Whiskers extend from the box to 1.53 the interquartile 838 
range. (c) Quantitative RT-PCR indicates that patients with KMT2B mutations (n = 4) have 839 
significantly decreased fibroblast mRNA levels of KMT2B when compared to controls (n = 840 
2) (Controls = 1.01±0.16SD; Patients = 0.57±0.12SD). n = 3 technical replicates were 841 
analyzed per sample. Data were analyzed by two-tailed unpaired t-test: *P = 0.0182 (t = 842 
3.856, df = 4). No significant difference in variances between the groups was detected by 843 
F-test. (d) Histone methylation was assayed independently in three samples (n = 3; 844 
technical replicates) taken from each patient-derived fibroblast cell line (n = 2; Patient 14 845 
and 16) on different days, and compared with control cell lines (n = 2). Methylation values 846 
are normalized to pan-histone H3 levels. Individual data-points are plotted with center bar 847 
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showing mean and error bars showing standard deviation. Differences between control 848 
and patient-derived samples are not significant (H3K4me3 (left): Controls = 849 
96.63±19.98SD; Patient 16 = 104.1±40.31SD; Patient 14 = 94.75±38.36SD; H3K4me2 850 
(right): Controls = 94.33±19.25SD; Patient 16 = 127.8±20.79SD; Patient 14 = 851 
80.23±31.09SD). Data were analyzed by one-way ANOVA: H3K4me3: P = 0.9196 (F = 852 
0.08462, DFn = 2, DFd = 9); H3K4me2: P = 0.0727 (F = 3.557, DFn = 2, DFd = 9). (e) 853 
Quantification of immunoblotting of tri-methyl H3K4 in Dictyostelium cell lysates. Tri-methyl 854 
H3K4 intensity values are normalized against levels of total histone H3. H3K4 tri-855 
methylation is impaired in set1- cells compared to wild type. Expression of GFP-DdSet1 or 856 
GFP-DdSet1(I1447T) in set1- cells rescues levels of H3K4Me3. Three independent point-857 
mutant cell lines (GFP-DdSet1(I1447T) 1-3) were created using the same point-mutant 858 
DNA construct. Individual data-points (three independently prepared samples taken from 859 
each cell line; n= 3, technical replicates) are plotted with center bar showing mean and 860 
error bars showing standard deviation (Wild type = 115±48.25SD; set1- = 5.94±9.37SD; 861 
set1- GFP-DdSet1(I1447T) 1 = 133.7±38.11SD; set1- GFP-DdSet1(I1447T) 2 = 862 
129.8±42.34SD; set1- GFP-DdSet1(I1447T) 3 = 96.07±31.82SD; set1- GFP-DdSet1 = 863 
110.5±12.02SD). No statistical testing was applied. 864 
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Table 1: KMT2B Variants and Evolution of Motor Phenotype in KMT2B-dystonia 865 
Pat Age 
(y) 
 
Sex 
M/F 
KMT2B variants(a) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
symptoms 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
1 14 
M 
Deletion: Chr19: 
35,608,666- 
36,233,508 
RLL 
Right foot posturing 
Gait disturbance 
4 6 6-11 5 Dysarthria 
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit No 
2 14 
F 
Deletion: Chr19: 
35,197,252- 
38,140,100 
Bilateral LL 
Limping 
Gait disturbance 
7 7 8-11 8 Dysarthria 
Dysphonia 
Drooling 
L-dopa trial – no benefit 
BLF – no benefit 
No 
3 9 
M 
Deletion: Chr19: 
34,697,740- 
37,084,510 
RLL 
Right foot posturing 
Gait disturbance 
2.5 3 6-7 4 Dysarthria 
Dysphonia 
Swallowing difficulties 
Drooling 
GBP – some reduction in 
tone 
No 
4 11 
F 
Deletion: Chr19: 
36,191,100- 
36,376,860 
LLL 
Left toe walking 
Gait disturbance 
4 8 9-12  5 Dysarthria 
Dysphonia 
Swallowing difficulties 
Drooling 
L-dopa trial– minimal 
benefit 
THP – minimal benefit 
Planned for 2016 
5 20 
M 
Deletion: Chr19: 
31,725,360- 
36,229,548 
Developmental 
delay  
Gait disturbance 
Present 
but age of 
onset not 
known 
Present 
but age of 
onset not 
known 
Present 
but age of 
onset not 
known 
Not known Nasal voice None No 
6 10 
F 
Deletion: Chr19: 
35,017,972- 
36,307,788 
RLL 
Right foot inversion 
2.5 4 4 4-7 Dysarthria/anarthria 
Jaw-opening dystonia 
Swallowing difficulties 
NGF 6y 
PEG 8y 
Torticollis 
Severe retrocollis 
 
L-dopa trial – no benefit 
THP – no benefit 
Inserted age 7y 
Sustained excellent 
clinical benefits 3y post-
DBS, marked 
improvement in 
torticollis, retrocollis, 
manual abilities and left 
leg dystonia. Loss of 
efficacy when ‘DBS off‘ 
for almost a year and 
functional recovery 
when switched on again.  
7 21 
M 
Deletion: Chr19: 
35,414,997- 
37,579,142 
RLL 
Right foot dragging 
Gait disturbance 
7 7-8 13 13 Dysarthria 
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
BLF – no benefit 
No 
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Pat Age 
(y) 
 
Sex 
M/F 
KMT2B variants (a) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
symptoms 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
8 17 
F 
Deletion: Chr19: 
35,414,997- 
37,579,142 
RLL 
Right foot posturing 
4 6 4-12 2.5 Dysarthria  
Dysphonia 
Drooling 
Torticollis 
L-dopa trial – no benefit Inserted age 10y 
Good response over 6 
years, particularly 
evident after 
replacement of faulty 
right DBS lead 
9 14 
M 
Deletion: Chr19: 
35,967,904- 
37,928,373 
Bilateral LL 
Gait disturbance 
4 4 9-13 9 Dysarthria 
Dysphonia 
L-dopa trial – possible initial 
benefit but not sustained 
Inserted age 14y 
Very good clinical 
response at 4m post-
DBS with restoration of 
independent ambulation 
10 7 
F 
Deletion: Chr19: 
35,794,775- 
38,765,822 
Bilateral LL 
Intermittent toe 
walking 
Gait disturbance 
4 4 - - - None No 
11 25 
F 
c.402dup 
p.Ser135Glnfs*23 
RUL 
Right hand cramps 
and posturing  
6 12 12 14(b)  Anarthria  
Orolingual dystonia  
Tongue thrusting 
Swallowing difficulties 
PEG 
L-dopa trial – poorly 
tolerated, no benefit 
 
Being considered 
12 6 
F 
 
c.1690C>T 
p.Arg564* 
Bilateral LL 
Toe walking 
4 5 6 5 Dysarthria 
Swallowing difficulties 
L-dopa trial – no benefit No 
13 11 
M 
c.3026_3027del 
p.Glu1009Glyfs*9 
 
Bilateral UL 
Posturing, tremor 
Difficulty handwriting 
8 9-10 8 9 Dysarthria  
Dysphonia 
 
L-dopa trial – no benefit No 
14 18 
M 
c.3143_3149del 
p.Gly1048Glufs*132 
 
Bilateral UL 
Posturing of hands 
Myoclonic jerks 
8 13 8 13 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit No 
15 20 
F 
c.4545C>A 
p.Tyr1515* 
Bilateral LL 
Toe Walking  
Clumsy 
 
 
2 9 9 8.5 Dysarthria  
Dysphonia 
Oromandibular dystonia 
Swallowing difficulties 
PEG 18y 
Moderate responses to 
(and currently taking)  
THP 
CLZ 
L-dopa 
BLF 
No 
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Pat Age 
(y) 
 
Sex 
M/F 
KMT2B variants (a) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
symptoms 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
16 6 
F 
c.4688del 
p.Ala1563Aspfs*83 
Bilateral LL 
Increasing falls 
Gait disturbance 
3 3 5 6 Dysarthria  
Dysphonia 
L-dopa trial – no benefit 
THP – initial benefit, not 
sustained 
No 
17 17 
M 
c.6515_6518delinsC
CCAA 
p.Val2172Alafs*11 
Bilateral LL 
Toe walking 
Gait disturbance 
1 1 8 12 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
TBZ – no benefit 
BLF and THP – mild benefit 
Inserted age 16y 
Very good clinical 
response 4m post-DBS 
with restoration of 
independent ambulation 
18 20 
F 
c.8061del 
p.Tyr2688Thrfs*50 
Clumsy movements 
Difficulties with 
speech articulation  
1 - - Infancy Dysarthria 
Dysphonia 
Swallowing and 
chewing difficulties 
No No 
19 28 
M 
c.8079del 
p.Ile2694Serfs*44 
Bilateral LL 
Toe walking 
Severe speech 
delay  
2 3 4 (L>R) 7 Anarthria 
Jaw opening dystonia 
Tongue protrusion 
Swallowing difficulties 
PEG 8y 
L torticollis,R laterocollis 
L-dopa trial – no benefit 
THP and TBZ reduced 
tongue protrusion  
Inserted age 27y 
Improvement of jaw 
opening dystonia and 
tongue protrusion  
20 40 
M 
c.3528+2T>A LLL 
Gait disturbance  
L foot dragging  
Clumsiness 
4 5 8 10 Severe dysarthria  
Dysphonia 
L torticollis 
L-dopa trial – no benefit 
TBZ, THP, SUL – no 
benefit 
 
Inserted age 32y – no 
benefit. Electrode 
replaced in 2009 with 
sustained improvement 
in foot posture but only 
transient benefit to 
cervical, UL and LL 
dystonia  
21 18 
M 
c.4955G>A 
p.Gly1652Asp 
RLL 
Right leg posturing 
 
6 8 12 5 Dysarthria  
Dysphonia 
Swallowing difficulties 
L-dopa trial – no benefit 
THP – not tolerated 
Inserted age 15y 
Sustained clinical 
benefit 3y post-DBS, 
improved dystonia and 
independent walking 
22 20 
F 
c.4986C>A 
p.Phe1662Leu 
RLL 
Right foot posturing 
Abnormal gait 
5 8 5-13 5-6 Dysarthria  
Dysphonia 
Swallowing difficulties 
Torticollis 
L-dopa trial – no benefit 
BLF – no benefit 
THP – low dose, mild 
benefit 
BTX neck – reduction in 
pain, no functional benefit 
Inserted age 20y 
Very good clinical 
response 9m post- DBS 
with improved dystonia 
and independent 
walking 
 868 
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Pat Age 
(y) 
 
Sex 
M/F 
KMT2B variants (a) Symptoms at 
presentation: 
Body distribution 
& motor features 
Onset of 
symptoms 
(y) 
 
Bilateral 
LL 
involve-
ment (y) 
Bilateral 
UL 
involve-
ment (y) 
Onset of 
cranial, 
cervical, 
laryngeal 
dystonia (y) 
Symptoms of cranial, 
cervical, laryngeal 
dystonia 
Trial of medication and 
clinical response 
Deep brain stimulation 
(DBS) 
 
23 8  
M 
c.5114G>A 
p.Arg1705Gln 
Bilateral LL 
Toe-walking 
3 3 6 6.5 Dysarthria 
Torticollis 
L-dopa trial – no benefit 
CLZ, THP, IT BLF – some 
benefit 
 
Inserted age 7y with 
considerable benefit 
24  27 
F 
c.5284C>T 
p.Arg1762Cys 
LLL 
Tiptoe walking and 
in-turning of L foot 
6 6 7  7 Dysarthria  
Anarthria from 14-15y  
Reduced tongue 
movements  
Swallowing preserved 
L-dopa trial – no benefit 
THP- no benefit  
No 
25 19 
F 
c.5342T>C 
p.Leu1781Pro 
RLL 
Right foot posturing 
Gait disturbance 
8 12 13 10 Dysarthria  
Dysphonia 
Swallowing difficulties 
Torticollis 
L-dopa trial – no benefit 
LVT – mild benefit 
Inserted age 19y 
Very good clinical 
response 4m post-DBS 
with improved dystonia 
and ambulation(c) 
26a 8 
M 
c.7549C>T 
p.Arg2517Trp 
Delayed speech 
Delayed motor 
development 
 
8 - - 8 Severe paroxysmal 
retrocollis and jaw 
dystonia 
- No 
26b 46 
F 
c.7549C>T 
p.Arg2517Trp 
Bilateral UL  
UL posturing 
Torticollis 
Inability to walk long 
distances and run 
23  26 23 23 Dysphonia  
Torticollis 
None No 
27 19 
F 
c.8021T>C 
p.Ile2674Thr 
RUL 
Posturing, tremor 
Difficulty handwriting 
Myoclonic jerks 
9 11-13 10 9-10 Dysphonia L-dopa trial – no benefit 
THP – no benefit 
LVT – no benefit 
CBZ – initial benefit, not 
sustained 
CLZ – not tolerated 
No 
BLF: baclofen; BTX: botulinum toxin; CLZ: clonazepam; GBP: gabapentin; IT: intrathecal; L: left; LL: lower limbs; LLL: left lower limb; LVT: levetiracetam; m: months; NGF: nasogastric 869 
feeding; Pat: patient; PEG: percutaneous endoscopic gastrostomy; R: right; RLL: right lower limb; RUL: right upper limb; SUL: sulpiride; UL: upper limbs; TBZ: tetrabenzine; THP: 870 
trihexyphenidyl; y: years 871 
(a) based on NCBI Reference Sequence: NM_014727.2 872 
(b) onset shortly after being fitted with orthodontic braces 873 
(c) had undergone 2 posterior cranial fossa explorations and palatal surgery before DBS 874 
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Table 2: Additional Clinical Features in Patient with KMT2B Variants 875 
Patient KMT2B variants Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
1 Deletion: Chr19: 
35,608,666-36,233,508 
38 Mild Elongated face Not reported Not reported Not reported Not reported 
2 Deletion: Chr19: 
35,197,252-38,140,100 
124 No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
3 Deletion: Chr19: 
34,697,740-37,084,510 
109 Moderate Elongated face Not reported Not reported Cutis aplasia(a) Retinal dystrophy 
4 Deletion: Chr19: 
36,191,100-36,376,860 
14 V mild - subtle 
memory problems  
Elongated face 
Broad nasal bridge 
Bulbous nasal tip 
Not reported Prone to 
anxiety(b) 
Not reported Not reported 
5 Deletion: Chr19:  
31,725,360-36,229,548 
110 Moderate Sparse hair 
Blepharophimosis 
Absent eyelashes of 
lower eyelids 
Low set, posteriorly 
rotated ears 
Epicanthic folds 
Narrow nasal 
bridge, ridge and 
point 
Largely bifid tongue 
Micrognathia 
Teeth overcrowding 
Finger contractures 
5th finger 
clinodactyly  
Toe over-riding  
Dysplastic toenails 
Microcephaly Not reported Occipital cutis aplasia  Small echogenic 
kidneys with low 
GFR, required renal 
transplant at 17 
years 
6 Deletion: Chr19: 
35,017,97-36,307,788 
69 No Not  
reported 
Microcephaly Not reported Not reported Not reported 
7 Deletion: Chr19: 
35,414,997-37,579,142 
99 Mild Elongated face Absence seizures Not reported Not reported Absent right testis 
8 Deletion: Chr19: 
35,414,997-37,579,142 
99 Mild 5th finger 
clinodacytly 
Not reported Not reported Ectodermal dysplasia Not reported 
9 Deletion: Chr19: 
35,967,904-37,928,373 
79 Mild Elongated face Strabismus Not reported Not reported Cleft palate 
10 Deletion: Chr19: 
35,794,775-38,765,822 
111 Moderate Not reported Strabismus  Not reported Not reported Short stature 
Bronchiectasis 
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 876 
Patient KMT2B variants Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
11 c.402dup 
p.Ser135Glnfs*23 
- No Bulbous nasal tip Not reported Not reported Not reported Not reported 
12 c.1690C>T 
p.Arg564* 
- Moderate Elongated face 
Bulbous nasal tip, 
short nasal root, 
Hypertelorism, large 
mouth with full 
lower lip 
Epilepsy Not reported Not reported Not reported 
13 c.3026_3027del 
p.Glu1009Glyfs*9 
- V mild - difficulties 
with attention 
Elongated face Not reported Not reported Not reported Not reported 
14 c.3143_3149del 
p.Gly1048Glufs*132 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
15 c.4545C>A 
p.Tyr1515* 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
16 c.4688del 
p.Ala1563Aspfs*83 
- No Elongated face Not reported Not reported Not reported Not reported 
17 c.6515_6518delinsCCCAA 
p.Val2172Alafs*11 
- No Elongated face Not reported Not reported Phimosos 
 
Short stature 
18 c.8061del 
p.Tyr2688Thrfs*50 
- Mild Micrognathia 
Atrophic tongue 
Bulbous nasal tip 
5th finger 
clinodacytly 
Not reported Not reported Not reported Not reported 
19 c.8079del 
p.Ile2694Serfs*44 
- No Short stature Delay in saccade 
initiation and 
hypometric vertical 
saccades 
ADHD(3) with no 
response to 
Ritalin 
Not reported Not reported 
20 c.3528+2T>A - Moderate 
6y- verbal IQ 74 
Performance IQ 
87 
No cognitive 
decline 
Not reported Not reported Not reported Not reported Not reported 
21 c.4955G>A 
p.Gly1652Asp 
- Mild Elongated face Not reported Not reported Not reported Short stature 
Hypertrichosis 
22 c.4986C>A 
p.Phe1662Leu 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
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 878 
Patient KMT2B variants Number of 
genes in 
microdeletion 
Intellectual 
disability 
Dysmorphic 
features 
Additional 
neurological 
features 
Psychiatric 
features 
Abnormal skin 
features 
Other systemic 
manifestations 
23 c.5114G>A 
p.Arg1705Gln 
- Mild-moderate  
6y WISC-IV 50-60 
Elongated face 
Bulbous nasal tip 
Broad philtrum, 
Upslanted eyes, 
epicanthus, low-set 
ears, periorbital 
fullness, gap 
between front teeth 
Spasticity in lower 
limbs from 6y  
Not reported Ichtyotic skin lesions 
with criss-cross 
pattern under the feet 
and at knees, broad 
scarring after 
operation 
Episodic vomiting 
24 c.5284C>T 
p.Arg1762Cys 
- No Short stature Oculomotor apraxia 
with difficulty 
initiating saccades. 
Mild spasticity 
No Not reported Not reported 
25 c.5342T>C 
p.Leu1781Pro 
- No Elongated face 
Bulbous nasal tip 
Not reported Not reported Not reported Not reported 
26a c.7549C>T 
p.Arg2517Trp 
- No Bulbous nasal tip None ADHD(c) 
Currently on 
methyphenidate,  
oxazepam, 
risperidone 
Not reported Not reported 
26b c.7549C>T 
p.Arg2517Trp 
- No Bulbous nasal tip Idiopathic 
intracranial 
hypertension – on 
acetazolamide 
None Not reported Not reported 
27 c.8021T>C 
p.Ile2674Thr 
- V subtle mild 
learning difficulties 
Bulbous nasal tip Not reported Anxiety 
Self-harm 
behavior 
Depression 
Obsessive-
compulsive 
traits(d) 
Not reported Not reported 
 879 
(a) Supplementary Figure 4c  880 
(b) Identified on formal psychology review 881 
(c) Diagnosed by psychiatrist and under regular psychiatry review 882 
(d) Under regular review with psychiatrist (ICD-10-CM F06.30; ICD-10-CM F42) 883 
ADHD: attention deficit hyperactivity disorder; GFR: glomerular filtration rate; V: very; y: years 884 
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ONLINE METHODS 885 
(1) Case Ascertainment 886 
Case ascertainment is summarized in Supplementary Table 1 and 887 
Supplementary Fig. 1. At Great Ormond Street-Institute of Child Health (GOS-888 
ICH), we identified 34 patients referred to our center with undiagnosed dystonia 889 
(Supplementary Table 1). All patients (median age 13.5 years), presented with 890 
progressive dystonia, with disease onset in childhood. None had a clinical history or 891 
neuroimaging compatible with acquired dystonia, nor blood, urine or CSF biomarker 892 
evidence of an underlying neurometabolic disorder. We used established national 893 
and international clinical genetic and pediatric neurology networks to identify further 894 
patients with microdeletions similar to those detected in the GOS-ICH cohort 895 
(Supplementary Fig. 1). We also collaborated with research groups undertaking 896 
whole exome sequencing in patients with early-onset dystonia (Supplementary 897 
Fig. 1). 898 
(2) Molecular Genetic Analysis 899 
Genomic DNA was extracted from peripheral lymphocytes by standard techniques. 900 
Written informed consent was obtained from participants, and all studies approved 901 
by local ethics committees: National Research Ethics Service (NRES), London 902 
Bloomsbury REC:13/LO/0168, Cambridge South REC:10/H0305/83; Republic of 903 
Ireland REC:GEN/284/12; Human Research Ethics Committee (HREC), 904 
HREC:10/CHW/114, 10/CHW/45; National Human Genome Research Institute 905 
Institutional Research Board 76-HG-0238; Universities of Essen-Duisburg and 906 
Erlangen-Nürnberg ethics committees Ref.3769; Medical Review Ethics Committee 907 
Region Arnhem-Nijmegen, Ref:2011/188; UCL ethics committee, UCLH 06/N076. 908 
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Research was performed in accordance with the Declaration of Helsinki. Additional 909 
consent for publication of photographs and videos was provided. 910 
Chromosomal Microarray 911 
Patients were analyzed for copy number variants using chromosomal microarray by 912 
standard diagnostic techniques (Supplementary Table 2). Data is presented as 913 
minimum coordinates in GRCh37/hg19. 914 
Whole Exome and Genome Sequencing (WES/WGS) 915 
WES/WGS was undertaken using center-specific protocols (see below). Reads 916 
were aligned to the reference genome GRCh37/hg19. Detailed variant analysis was 917 
performed for single nucleotide variants (SNVs) and small insertion/deletions 918 
(indels) that (i) passed standard local quality filters, (ii) were predicted to alter 919 
protein sequence in conserved residues, (iii) were predicted deleterious by 920 
bioinformatics tools (including SIFT, PolyPhen-2, LRT, Mutation Taster, CADD), (iv) 921 
had an allele frequency <0.01 in 1000 Genomes41, NHLBI GO Exome Sequencing 922 
Project, UK10K42, Exome Aggregation Consortium (ExAC) database8 and internal 923 
control exomes/genomes. Data analysis was initially undertaken for known disease-924 
causing genes prior to analysis for autosomal recessive and dominant inheritance 925 
models. 926 
NIHR BioResource-Rare Diseases (NIHRBR-RD) Study: WGS was undertaken 927 
using the Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., 928 
San Diego, CA, USA) on Illumina Hiseq 2500, generating minimum coverage of 929 
15X for ~95% of the genome, and average coverage of ~30X. Reads were aligned 930 
using Isaac aligner (version 01.14) (Illumina Inc, Great Chesterford, UK)43. SNVs 931 
and indels were identified using Isaac variant caller (version 2.0.17).  932 
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Wellcome Trust UK10K Rare Diseases project: DNA samples were captured using 933 
Agilent SureSelect Target Enrichment V5 (Agilent Technologies, Santa Clara, CA, 934 
USA) pull-down array. WES was performed on Illumina HiSeq 2000 platform. 935 
Reads were aligned using the Burrows-Wheeler Alignment tool. SNVs and indels 936 
were identified with SAMtools44,45. Variants were identified for each sample using 937 
the Genome Analysis Toolkit (GATK) Unified Genotyper46 and annotated with vcf-938 
annotate47 and Ensembl Variant Effect Predictor v73 (VEP)48.  939 
National Institutes of Health, Bethesda: Exome sequencing was completed using 940 
the TruSeqV2 exome capture kit. Data was aligned and processed as previously 941 
decribed49-51.  942 
Institute of Human Genetics, Erlangen: Exome sequencing was performed on a 943 
HiSeq 2500 (Illumina) platform with 125 bp paired-end sequencing using 944 
SureSelect v.5 capturing reagents (Agilent).  945 
Radboud University Medical Center, Nijmegen: Exome sequencing was undertaken 946 
using Agilent SureSelectXT Human All Exon 50 Mb Kit, with sequencing on SOLiD 947 
5500XL, producing an average sequence depth of 91X and average coverage of at 948 
least 20X for 89% of targets. For calling and annotation of variants, a custom in-949 
house diagnostic pipeline was deployed52. 950 
UCL-Institute of Neurology, London: Exome sequencing was performed using 951 
Illumina’s Nextera Rapid Capture. Indexed and pooled libraries were sequenced on 952 
Illumina’s HiSeq3000 (100bp, paired-end). Reads were aligned with Novoalign. 953 
Duplicate read removal, format conversion, and indexing were performed with 954 
Picard. GATK was used to recalibrate base quality scores, perform local 955 
realignments around possible indels, and to call (HaplotypeCaller) and filter (VQSR) 956 
variants46. Annotated variant files were generated using ANNOVAR53.  957 
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Deciphering Developmental Disorders study: Exome sequencing of family triomes 958 
was performed using Agilent SureSelect Exome bait design (Agilent Human All-959 
Exon V3 Plus with custom ELID C0338371 and Agilent Human All-Exon V5 Plus 960 
with custom ELID C0338371) on a Illumina HiSeq at the Wellcome Trust Sanger 961 
Institute as previously described54,55. Data is currently available on 4,295 triomes 962 
which were interrogated via a DDD complementary research proposal (CAP#120). 963 
Sanger Sequencing for Variant Validation and Gene Screening 964 
Direct sequencing was undertaken to (i) screen the entire coding region of KMT2B 965 
for 13 cases from the GOS-ICH cohort (Supplementary Table 1), (ii) confirm 966 
variants identified on next generation sequencing and (iii) establish familial 967 
segregation (Supplementary Fig. 2). Additionally, cDNA from fibroblasts and 968 
patient derived dopaminergic neurons were sequenced for a common SNP in exon 969 
30 (rs231591). Primer pairs for all 37 coding exons and exon/intron boundaries of 970 
KMT2B (Ensembl ENSG00000272333, transcript ENST00000420124) were 971 
designed with Primer3 (Supplementary Table 9)56,57. PCR conditions can be 972 
provided on request. PCR products were cleaned up (MicroCLEAN, Web Scientific) 973 
and sequenced using the Big Dye Terminator Cycle Sequencing System (Applied 974 
Biosystems Inc.). Sequencing reactions were run on an ABI PRISM 3730 DNA 975 
Analyzer (Applied Biosystems Inc.) and analyzed using Chromas.  976 
Enrichment Analysis 977 
The number of de novo predicted protein truncating variants (PPTVs) in KMT2B 978 
expected to be seen by chance in a subset of the NIHR BioResource–Rare 979 
Diseases cohort with pediatric onset neurological disease (n=272), was calculated 980 
using published gene-specific mutation rates58 and scaled to account for frameshift, 981 
nonsense and essential splice site variants58. To assess significance, the expected 982 
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number of de novo PPTVs were compared to the observed number, assuming a 983 
Poisson distribution. 984 
(3) CSF Neurotransmitter Analysis 985 
CSF was collected by lumbar puncture and diagnostically analyzed for 986 
neurotransmitter monoamine metabolites in specialist laboratories (London, 987 
Barcelona, Sydney, Jerusalem) by high performance liquid chromatography59.60  988 
(4) Comparative Modelling 989 
In silico homology modeling was utilized to predict putative effects of KMT2B 990 
variants. The Pfam database61 was used to assign known domains to the full-length 991 
sequence of KMT2B. Evolutionary conservation of residues in the sequence was 992 
quantified using Consurf server62, based on alignment with a set of homologous 993 
sequences, which share 35%-95% sequence identity with KMT2B. HHpred63 was 994 
utilized to identify proteins or domains with known structure that have similar 995 
sequence and structural features to KMT2B. Selected templates had more than 996 
99% probability (based on HHpred alignment score) of being related structurally to 997 
specific domain segments of KMT2B. MODELLER64 was employed for different 998 
regions of KMT2B and HHpred alignments were used to dictate residue 999 
equivalences with the template. For each domain, 150 models were generated with 1000 
MODELLER loop optimization protocol and the best model was selected based on 1001 
the normalized DOPE score65. The effect of a point substitution on the stability of 1002 
the domain structure was evaluated using DUET11 and MAESTRO10. Visualization 1003 
and analysis of amino acid interactions and generation of mutant models were done 1004 
with UCSF Chimera66. 1005 
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(5) Histone Methylation Assays 1006 
H3K4 Methylation  1007 
Histones were extracted from fibroblasts using a modified version of a published 1008 
protocol67. Cells were lysed by rotating at 4°C in hypotonic lysis buffer (10mM Tris-1009 
Cl pH8.0, 1mM KCl, 1.5mM MgCl2, 1mM DTT, Roche complete protease inhibitors). 1010 
Intact nuclei were pelleted by centrifugation and resuspended in 0.2N HCl. 1011 
Following overnight histone extraction by rotating at 4°C, nuclear debris was 1012 
removed by centrifugation and soluble histones precipitated by dropwise addition of 1013 
TCA to a final concentration of 33%. Following one hour precipitation on ice, 1014 
histones were pelleted by centrifugation and washed with acetone before 1015 
resuspension in Milli-Q water.  1016 
Expression of p.Ile1447Thr Set1 Point Substitution in Dictyostelium 1017 
Dictyostelium discoideum cells were grown as previously described68. They are not 1018 
listed in the database of commonly misidentified cell lines maintained by ICLAC. 1019 
Dictyostelium strains69 included wild type—AX2 (DBS0238015) and set1-KO—set1- 1020 
(DBS0236928). DdSet1 has Dictybase gene ID DDB_G0289257 and Uniprot ID 1021 
Q54HS3. p.Ile1447Thr was created by substituting ATT for ACT in a DdSet1 1022 
genomic clone by PCR (Supplementary Table 10). The product containing this 1023 
substitution was cloned as a ClaI/EcoRI fragment replacing the equivalent region of 1024 
a wild type DdSet1 genomic clone. This region was subsequently subcloned as a 1025 
ClaI/AccI fragment into a pDEXH70 based integrating plasmid containing GFP-1026 
DdSet1 under control of the DdAct15 promoter and a G418 selection marker – 1027 
replacing the same region of the wild type DdSet1 cDNA sequence. The presence 1028 
of p.Ile1447Thr in the resulting plasmid, pJN106, was confirmed by Sanger 1029 
sequencing. Constructs for expression of GFP-DdSet1(p.Ile1447Thr) (pJN106) and 1030 
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wild type GFP-DdSet1 (pJRC18) were transformed into set1- Dictyostelium cells71 1031 
as previously described68. Transformants were selected by addition of 10ug/ml 1032 
Geneticin (Gibco) to growth medium. Expression of full-length wild type and point 1033 
mutant GFP-DdSet1 was confirmed by anti-GFP immunoblotting. 1034 
Immunoblot Analysis of Histone Methylation 1035 
Fibroblast histone samples were diluted in SDS sample buffer (Bio-Rad) containing 1036 
5% [v/v] β-mercaptoethanol and protease inhibitors (Roche Complete), separated 1037 
by SDS-PAGE, then blotted onto nitrocellulose. Histone H3 and methylated K4 1038 
variants were detected using rabbit polyclonal anti-histone H3 (Abcam ab1791, 1039 
1:1000 dilution), rabbit polyclonal anti-histone H3 tri-methyl K4 (Abcam ab8580, 1040 
1:1000 dilution), rabbit polyclonal anti-histone H3 di-methyl K4 (Millipore 07-030, 1041 
1:2000 dilution). Secondary antibody used was donkey anti-rabbit IgG HRP-1042 
conjugated (GE Healthcare NA934V; for Histone H3 and tri-methyl K4 detection 1043 
1:30000 dilution, for di-methyl K4 detection 1:20000 dilution). Following detection 1044 
using Supersignal West Pico chemiluminescent substrate (Thermo) and CL-1045 
Xposure film (Thermo), densitometry was performed using ImageJ72. 1046 
Dictyostelium cells were collected by centrifugation and resuspended in KK2 1047 
buffer68 before lysis in SDS sample buffer (Bio-Rad) containing 5% [v/v] β-1048 
mercaptoethanol and protease inhibitors (Roche Complete). Immunoblotting for 1049 
GFP-DdSet1 expression was assayed as above, using a mouse IgG monoclonal 1050 
anti-GFP primary (Roche 11814460001, 1:500 dilution) and anti-mouse IgG HRP-1051 
conjugated secondary antibody (BioRad 170-6516, 1:20000 dilution). 1052 
Immunoblotting for Histone H3 and tri-methyl H3K4 was conducted as for 1053 
fibroblasts (with the modification: anti-histone H3 tri-methyl K4 dilution 1:3000). 1054 
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(6) RNA and Protein Measurements  1055 
Fibroblast RNA Extraction and cDNA Synthesis 1056 
Skin biopsies from Patients 2, 13, 14 and 16 were taken for fibroblast culture, and 1057 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) with 4.5g/L glucose, 1058 
4mM L-glutamine, and 10% heat inactivated fetal bovine serum (Life Technologies) 1059 
and maintained in an incubator at 37°C and 5% CO2. Fibroblasts from two age-1060 
matched controls were supplied by the Dubowitz Neuromuscular Centre Biobank 1061 
(GOS-ICH). Cultures were checked for mycoplasma contamination (MycoAlert 1062 
Mycoplasma Detection Kit, Lonza). As fibroblast cultures were derived from human 1063 
skin biopsies, no authentication was undertaken. Furthermore these cell lines do 1064 
not belong to the commonly misidentified cell lines listed in the database 1065 
maintained by ICLAC. RNA was extracted from fibroblasts of T75 cell culture flasks 1066 
using the RNeasy Mini Kit from QIAGEN. First-Strand cDNA synthesis was carried 1067 
out with SuperScript® III Reverse Transcriptase (Invitrogen) using 500ng total RNA 1068 
per reaction and Oligo (dT) primers (Thermo Fisher Scientific).  1069 
Generation of Dopaminergic Neurons, RNA Extraction, cDNA Synthesis 1070 
Fibroblasts from a KMT2B-negative individual were reprogrammed into induced 1071 
pluripotent stem cells (iPSC) using an established Sendai virus protocol 1072 
(CytoTune®-iPS Reprogramming Kit, Invitrogen)73. iPSC lines were stringently 1073 
tested for pluripotency using established methods74 before differentiation into 1074 
dopaminergic neurons75. After 60 days of differentiation, dopaminergic identity was 1075 
confirmed by immunofluorescence for neuronal marker, MAP2, (mouse monoclonal 1076 
anti-MAP2, Sigma, M9942, 1:400 dilution) and dopaminergic marker, TH (chicken 1077 
polyclonal anti-TH, Aves labs, TYH, 1;400 dilution). Nuclei were contrasted with 1078 
DAPI. Microscopic images were captured (Zeiss LSM710 Confocal) and analyzed 1079 
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using ImageJ72. Neuronal differentiation efficiency was determined by calculating 1080 
the number of MAP2/TH positive cells relative to MAP2-positive cells 1081 
(Supplementary Fig. 14). RNA extraction and cDNA synthesis was carried out as 1082 
described for fibroblasts. 1083 
PCR Analysis 1084 
We investigated tissue expression of KMT2B in (i) human fetal cDNA samples 1085 
(Moore fetal tissue cohort)76, (ii) a human cDNA panel (Clontech), (iii) human 1086 
fibroblasts and (iv) dopaminergic neurons differentiated from human iPSC. PCR 1087 
amplification of cDNA (Supplementary Table 11) was performed with BioMix™ 1088 
Red (Bioline Ltd, conditions available on request). PCR products were separated on 1089 
a 2% agarose gel containing Ethidium bromide (Sigma) and visualized with Gel 1090 
Doc™ XR+ System (Bio Rad). 1091 
Changes in relative expression of KMT2B, THAP1 and TOR1A, were measured by 1092 
quantitative RT-PCR on a StepOnePlus™ Real-Time PCR System (Applied 1093 
Biosystems). RT-PCR reactions comprised 1x MESA Blue qPCR MasterMix Plus 1094 
for SYBR® Assay (Eurogentec), 0.1µl ROX Reference Dye (Invitrogen), 9μL cDNA 1095 
(of a dilution 1:25) and 500nM of each primer (Supplementary Table 11). RT-PCR 1096 
conditions are available on request. Relative quantification of gene expression was 1097 
determined using the 2−∆∆Ct method77, with glyceraldehyde-3-phosphate 1098 
dehydrogenase (GAPDH) as a reference gene. 1099 
Fibroblast Protein Preparation and Immunoblot Analysis 1100 
Fibroblasts grown in T25 cell culture flasks were washed with cold PBS and 1101 
incubated with lysis buffer [150mM NaCl, 50mM Tris pH8, 1% NP40 and 1x 1102 
cOmplete™ Mini Protease Inhibitor Cocktail (Roche)] for 30 minutes on ice. Lysed 1103 
cells were centrifuged at 13,000 rpm for 15 minutes to remove cell debris. Protein 1104 
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concentrations of the cell lysates were measured with the Pierce™ BCA Protein 1105 
Assay Kit (Thermo Fisher Scientific). A total of 5-10ng protein were prepared with 1106 
1x Laemmli buffer and 0.5M DTT and boiled for 5 minutes at 100°C for denaturing. 1107 
Proteins were separated by electrophoresis on 4–20% Mini-PROTEAN® TGX 1108 
Stain-Free™ Protein Gels (Bio Rad) by applying 300V for ~17 minutes. Proteins 1109 
were transferred to polyvinylidene difluoride (PVDF) membranes (Bio Rad) using 1110 
the Trans-Blot® Turbo™ Transfer System (Bio Rad). Membranes were incubated 1111 
for 1 hour at room temperature in blocking solution (5% nonfat dry milk in 1112 
Phosphate-buffered saline-Tween 20, PBS-T) and then probed with polyclonal 1113 
rabbit anti-THAP1 (Cambridge Bioscience [Supplier: Proteintech], 12584-1-AP, 1114 
1:1500 dilution) and monoclonal mouse anti-TorsinA (Cell Signaling, D-M2A8, 1115 
1:1000 dilution), respectively, in blocking buffer (1% nonfat dry milk in PBS-T; 1116 
except THAP1 antibody which was diluted in 5% nonfat dry milk in PBS-T) for 1117 
approximately 16 hours at 4°C. Following three washing steps with PBS-T, 1118 
membranes were incubated for 1 hour at room temperature with horseradish 1119 
peroxidase (HRP)-conjugated goat anti-rabbit IgG antibody (Cell Signaling, #7074, 1120 
1:3000 dilution) and HRP-conjugated horse anti-mouse IgG antibody (Cell 1121 
Signaling, #7076, 1:3000 dilution), respectively. Afterwards the blot was washed 1122 
three times with PBS-T and signals were visualized with ClarityTM ECL Western 1123 
Blotting Substrate (Bio Rad) on a Gel Doc™ XR+ System (Bio Rad). To confirm 1124 
equivalent loading, blots were stripped at 37°C for 15 minutes in RestoreTM Western 1125 
blot Stripping buffer (Thermo Fisher Scientific), blocked for 1 hour, and reprobed 1126 
with HRP-conjugated rabbit anti-β-Tubulin (Cell Signaling, 9F3, 1:1000 dilution). For 1127 
quantification, intensity values of control and patient bands were determined using 1128 
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Fiji software78 and normalized against the intensity value of the reference protein 1129 
band. 1130 
CSF Immunoblotting 1131 
CSF protein levels of tyrosine hydroxylase (TH) and dopamine receptor D2 (D2R) 1132 
were analyzed. CSF samples were available from two patients (Patients 2 and 16) 1133 
and four gender and age-matched controls (patients with no history of movement 1134 
disorder, on no medication). Immunoblotting was carried out as described above. 1135 
For the detection of TH and D2R the membranes were incubated with polyclonal 1136 
rabbit anti-TH (Millipore, AB152, 1:1000 dilution) and polyclonal rabbit anti-D2R 1137 
(Millipore, AB5084P, 1:1000 dilution), respectively, followed by 2 hours incubation 1138 
with HRP-conjugated goat anti-rabbit IgG antibody (Cell Signaling, #7074, 1:3000 1139 
dilution). As an internal control for loading monoclonal mouse anti-Transferrin 1140 
(Santa Cruz, E-8, 1:1000 dilution) followed by HRP-conjugated horse anti-mouse 1141 
IgG antibody (Cell Signaling, #7076, 1:3000 dilution) were used. 1142 
(7) Statistics 1143 
The statistical analyses for the histone methylation assays were conducted using 1144 
GraphPad Prism v7.01 and for the analyses of the fibroblast cell lines and CSF 1145 
immunoblotting using GraphPad v5. The final data are represented with the mean 1146 
and the standard deviation as error bars. For multiple comparisons one-way 1147 
ANOVA was performed whereas for dual comparisons unpaired two-tailed 1148 
Student’s t test were employed. P < 0.05 was considered significant: *P < 0.05, **P 1149 
< 0.01, ***P < 0.001. The F test was utilized to compare the variances between the 1150 
groups in dual comparisons. 1151 
We assume that technical replicates of immunoblot assays using the same cell 1152 
lines will be normally distributed. For the fibroblast histone methylation assay the 1153 
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Brown-Forsythe test was used to check differences in variance between the groups 1154 
compared, and no significant differences was found in standard deviation 1155 
(H3K4Me3: p = 0.7567 [F = 0.2877, DFn = 2, DFd = 9]; H3K4me2: p=0.8446 [F = 1156 
0.1721, DFn = 2, DFd = 9]). For the remaining experiments data distribution was 1157 
not tested but was assumed to be normal. Blinding was not applied for data 1158 
collection and analysis. 1159 
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